

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066613 A1

(51) International Patent Classification⁷: **C07D 295/12**,
C07C 237/40, C07D 401/04, C07C 233/80

(21) International Application Number: PCT/EP03/01188

(22) International Filing Date: 6 February 2003 (06.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0202873.6 7 February 2002 (07.02.2002) GB

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LOISELEUR, Olivier** [CH/FR]; 4, rue de Genève, F-68300 Saint-Louis (FR). **KAUFMANN, Daniel** [CH/CH]; Im Wilacker 21, CH-4106 Therwil (CH). **ABEL, Stephan** [DE/DE]; Alemannenweg 12, 79576 Weil am Rhein (DE). **BUERGER, Hans, Michael** [CH/DE]; Maiengasse 28, CH-4123

Allschwil (CH). **MEISENBACH, Mark** [DE/FR]; 11, rue de Chemin de Fer, F-68480 Durmenach (FR). **SCHMITZ, Beat** [CH/CH]; Meiengasse 27, CH-4123 Allschwil (CH). **SEDELMEIER, Gottfried** [DE/DE]; Erlenweg 11, 79227 Schallstadt (DE).

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066613 A1


(54) Title: **N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES**

(57) Abstract: The present invention relates to novel amides and a process for preparing these amides.

N-phenyl-2-pyrimidine-amine derivatives

The present invention provides novel amides, a process for preparing these amides and the use of these amides.

In particular, the present invention provides novel amides of formula I



wherein

one of the radicals R_1 , R_2 , R_3 , R_4 and R_5 is

- a) a radical selected from the group consisting of lower alkyl, amino; mono- or di-lower alkylamino; lower alkanoylamino; lower alkoxy-carbonyl; and lower alkyl which is substituted by amino, mono- or di-lower alkylamino or lower alkanoylamino, or
- b) an unsubstituted or substituted radical selected from the group consisting of benzylamino; benzoylamino; pyrrolidinyl; piperidyl; piperazinyl; piperazinyl-carbonyl; morpholinyl, thiomorpholinyl; and lower alkyl substituted by benzylamino, benzoylamino, halogene, pyrrolidinyl, piperidyl, piperazinyl, e.g. 4-methyl-piperazinyl-, thiomorpholinyl, or morpholinyl, the substituents of said substituted radical being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen, and

and the other four radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

or

R_1 and R_2 , R_2 and R_3 , R_3 and R_4 , or R_4 and R_5 together are a substituted or unsubstituted alkylene radical having 4 carbon atoms, the substituents preferably being selected from

- 2 -

cyano, unsubstituted or hydroxy-, amino- or 4-methyl-piperazinyl-substituted lower alkyl, such as especially methyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino and free or esterified carboxy;

and the other three radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

and one of the radicals R_6 , R_7 and R_8 is halogen, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, $NHC(NH)NH_2$, and the other two radicals are independently hydrogen, lower alkyl, lower fluorinated alkyl, benzyl or phenyl;

or a salt or crystal form thereof.

Compounds of formula I may be in the form of a salt preferably a pharmaceutically acceptable salt.

Such salts are formed, for example, as acid addition salts, preferably with organic or inorganic acids, from compounds of formula I or IV with a basic nitrogen atom, especially the pharmaceutically acceptable salts. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid. Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, octanoic acid, decanoic acid, dodecanoic acid, glycolic acid, lactic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azelaic acid, malic acid, tartaric acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, cyclohexanecarboxylic acid, adamantanecarboxylic acid, benzoic acid, oxalic acid, salicylic acid, 4-aminosalicylic acid, phthalic acid, phenylacetic acid, mandelic acid, cinnamic acid, methane- or ethane-sulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1,5-naphthalene-disulfonic acid, 2-, 3- or 4-methylbenzenesulfonic acid, methylsulfuric acid, ethylsulfuric acid, dodecylsulfuric acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.

- 3 -

For isolation or purification purposes it is also possible to use pharmaceutically unacceptable salts, for example picrates or perchlorates. For therapeutic use, only pharmaceutically acceptable salts or free compounds are employed (where applicable in the form of pharmaceutical preparations), and these are therefore preferred.

Preferred salts of formula I, are chloride, bromide, mesylate, acetate, trifluoroacetate.

The term "lower" within the scope of this application denotes radicals having up to and including 7, preferably up to and including 4 carbon atoms, preferably methyl or ethyl.

The term "lower fluorinated alkyl" within the scope of this application denotes radicals having up to and including 7, preferably up to and including 4 carbon atoms, preferably methyl or ethyl, which are substituted by fluorine such as mono, di or trifluoro-methyl, trifluoro-ethyl.

The term "piperazinyl" within the scope of this application denotes unsubstituted piperazinyl or N-lower alkyl-piperazinyl such as 4-methyl-piperazinyl-.

Halogen is especially fluorine, chlorine, bromine, or iodine, especially fluorine, chlorine, or bromine.

Etherified hydroxy is preferably lower alkoxy. Esterified hydroxy is preferably hydroxy esterified by an organic carboxylic acid, such as a lower alkanoic acid, or a mineral acid, such as a hydrohalic acid, for example lower alkanoyloxy or especially halogen, such as iodine, bromine or especially fluorine or chlorine.

Alkylated amino is, for example, lower alkylamino, such as methylamino, or di-lower alkylamino, such as dimethylamino. Acylated amino is, for example, lower alkanoylamino or benzoylamino.

Esterified carboxy is, for example, lower alkoxycarbonyl, such as methoxycarbonyl.

Preferably, R_3 is lower alkyl substituted by benzylamino, benzoylamino, halogene, pyrrolidinyl, piperidyl, piperazinyl, e.g. 4-methyl-piperazinyl-, or morpholinyl, thiomorpholinyl, the substituents of said substituted radical being selected from the group consisting of

- 4 -

cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxycarbonyl and halogen.


Preferably, R_3 is lower alkyl substituted by pyrrolidinyl, piperidyl, piperazinyl, e.g. 4-methyl-piperazinyl-, or morpholinyl, thiomorpholinyl, the substituents of said substituted radical being selected from the group consisting of lower alkyl; hydroxy- or amino-substituted lower alkyl;

Preferably, R_1 , R_2 , R_4 , R_5 and R_8 are hydrogen.

Preferably, R_7 is lower alkyl such as methyl or fluorinated alkyl such as trifluoromethyl.

Most preferably, R_3 is (4-methyl-piperazinyl)-methyl, R_1 , R_2 , R_4 , R_5 and R_8 are hydrogen, R_6 is halogen, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, $NHC(NH)NH_2$, and R_7 is methyl.

Amides of formula I may be prepared by a process as depicted below:



wherein R_1 to R_8 are as defined above and R_9 is hydrogen, methyl, ethyl or aryl.

However, direct conversion of unactivated carboxylic acids or esters to amides, such as compounds of formula II, with amines is difficult and typically requires high reaction temperature, e.g. of about $200^\circ C$, or use of strong bases, such as sodium methoxide, sodium amide, *n*-butyl lithium, sodium hydride or Grignard reagent. Thus there is a need for a more efficient amidation process as hitherto known.

- 5 -

The present Applicants have found that direct conversion of unactivated carboxylic acids or esters of compounds of formula II with compounds of formula III to amides of formula I may successfully be conducted under mild conditions

A) where R_9 is methyl, ethyl or aryl:

in the presence of

- 1) a Lewis acid,
- 2) an aprotic organic solvent, and optionally
- 3) a base,

at a temperature of between 20°C and 80°C, preferably at about 40°C, for a period of between 1 hour and 1 day, preferably 8 hours, preferably under inert atmosphere, preferably at atmospheric pressure, and hydrolysis of the resulting product; or

B) where R_9 is hydrogen:

in the presence of

- 1) thionylchloride,
- 2) an aprotic organic solvent, and optionally
- 3) a base,

at a temperature of between 20°C and 70°C, preferably 45°C, for a period of between 1 hour and 1 day, preferably 6 hours, preferably under inert atmosphere, preferably at atmospheric pressure.

Thus, the present invention provides in another aspect processes for the preparation of a compound of formula I by reacting compounds of formula II with compounds of formula III

A) where R_9 is methyl, ethyl or aryl:

in the presence of

- 1) a Lewis acid,
- 2) an aprotic organic solvent, and optionally
- 3) a base

at a temperature of between 20°C and 80°C, preferably at about 40°C, for a period of between 1 hour and 1 day, preferably 8 hours, preferably under inert atmosphere, preferably at atmospheric pressure, and the resulting product is hydrolyzed; or

B) where R_9 is hydrogen:

in the presence of

- 1) thionylchloride,
- 2) an aprotic organic solvent, and optionally

- 6 -

3) a base,

at a temperature of between 20°C and 70°C, preferably 45°C, for a period of between 1 hour and 1 day, preferably 6 hours, preferably under inert atmosphere, preferably at atmospheric pressure.

Suitable Lewis acids for process A) include Al(lower alkyl)₃ (e.g. AlMe₃, AlEt₃, Al(*i*Bu)₃), AlCl₃, AlBr₃, EtAlCl₂, MeAlCl₂, Me₂AlCl, Et₂AlCl and the corresponding sesquichlorides. Preferably, the Lewis acid is selected from AlCl₃, EtAlCl₂ or Et₂AlCl, even more preferably is AlCl₃. Typically, the Lewis acid is present in an amount of 1 to 4 mole equivalents. In the case of AlMe₃, AlEt₃, and Al(*i*Bu)₃, e.g. 2 to 3 mole equivalents, preferably about 2.5 mole equivalents are present; in the case of AlCl₃, AlBr₃, EtAlCl₂, MeAlCl₂, Me₂AlCl, Et₂AlCl and the corresponding sesquichlorides, preferably 1.5 to 3.5, preferably 2.5 mole equivalents are present.


Thionylchloride is preferably present in process B) in an amount of 1.5 to 10 mole equivalents, preferably 1.5 mole equivalents.

Suitable aprotic organic solvents for carrying out process A) and B) include toluene/acetonitrile, toluene, benzene, chlorobenzene, dichlorobenzene, acetonitrile, mesitylene and pyridine.

A preferred base for process A) or B) is N,N-diisopropylethylamine, lutidine, pyridine, or tertiary amines.

In an alternative aspect, the present invention provides a process for the preparation of compounds of formula I by reacting compounds of formula V with compounds of formula R₁₄-H

- 7 -



wherein,

R₁₃ is a lower alkyl substituted by a halogen,

R₁₄ is benzylamino, benzoylamino, pyrrolidinyl, piperidyl, piperazinyl, optionally substituted by radicals being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl,

R₃ is a lower alkyl substituted by benzylamino, benzoylamino, pyrrolidinyl, piperidyl, piperazinyl, optionally substituted by radicals being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl.


The reaction is preferably carried out in the presence of an organic solvents, such as THF (Tetrahydrofuran) or directly in the amine solution R₁₄-H.

Preferably piperazinyl is a N-lower-alkylpiperazine e.g. N-methylpiperazine.

Preferably, R₁, R₂, R₄ and R₅ are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxycarbonyl and halogen.

Compounds of formula V can be obtained by reacting compounds of formula II' with compounds of formula III,

- 8 -



in the presence of

- 1) an organic solvent such as THF (Tetrahydrofuran)
- 2) a base such as N,N-diisopropylethylamine, lutidine, pyridine, or tertiary amines.


Alternatively, R₁₄-H is directly added in the reactional medium without further purification in order to react with the resulting compound of formula V.

THF can be used alone or in mixtures with other solvents to increase overall solvent power.

The amides of formula I may be formed and isolated from the reaction mixture, e.g. as conventional, e.g. by removal of solvent from the reaction mixture, e.g. by concentration such as evaporation, e.g. to dryness or almost dryness, e.g. until crystallization or precipitation of an amide of formula I occurs; or by extraction, e.g. as a salt, or into another solvent which may be the same or different from that used in the amidation; and precipitation or crystallization of an amide of formula I. The amides of formula I may be purified by conventional techniques such as recrystallization or chromatography.

Compounds of formula II or II' may be prepared by methods known to the skilled person in the art. Compounds of formula III are commercially available e.g. from Fluka, Aldrich or Acros or may be prepared by methods known to the skilled person in the art.


The compounds of formula I may be used for the preparation of compounds of formula IV,



wherein R₁ to R₅ are as defined above and

- 9 -

one of the radicals R_6' , R_7' and R_8' is



wherein R_{10} is 4-piperazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen, and R_{11} and R_{12} are each independently of the other hydrogen or lower alkyl

and the other two radicals are independently hydrogen, lower alkyl, e.g. methyl, benzyl or phenyl;

or a pharmaceutically acceptable salt or crystal form thereof.

Compounds of formula IV may be in the form of a salt, preferably a pharmaceutically acceptable salt, as described above.


Preferred salts are for example chloride, bromide, mesylate, acetate, trifluoroacetate.

Compounds of formula IV inhibit the tyrosine kinase activity of the receptor for the epidermal growth factor (EGF) and are useful, inter alia, for the treatment of benign or malignant tumors. They are able to effect tumour regression and to prevent metastatic spread and the growth of micrometastases. In particular, they can be used for treating epidermal hyperproliferation (psoriasis), for treating neoplasms of epithelial character, e.g. mastocarcinoma, and leucemia. In addition, the compounds of formula IV are useful for treating diseases of the immune system and inflammations, subject to the involvement of protein kinases. The compounds of formula IV may also be used for treating diseases of the central or peripheral nervous system, subject to the involvement of signal transmission by protein kinases.

Thus, in another aspect the present invention provides a process for the preparation of compounds of formula IV from compounds of formula I and the use of compounds of formula I for the preparation of compounds of formula IV wherein R_1 to R_8' are as herein described.

- 10 -

This invention relates to a process for the preparation of a compound of formula IV or a pharmaceutically acceptable salt or crystal form thereof, by reacting a compound of formula I as described herein, with a compound of formula VII



VII


wherein R_{10} is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom e.g. 3-pyridyl and unsubstituted or substituted at the nitrogen atom by oxygen, and R_{11} and R_{12} are each independently of the other hydrogen or lower alkyl, by conventional methods.

Preferably in a first step, the compound of formula I is prepared from compounds of formula II and III as described herein.

The present invention also relates to a process for the preparation of a compound of formula IV or a pharmaceutically acceptable salt or crystal form thereof,

by reacting a compound of formula I as described herein, wherein the radical R_6 is - $NHC(NH)NH_2$,

with a compound of formula VI



VI

wherein R_{10} is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom e.g. 3-pyridyl and unsubstituted or substituted at the nitrogen atom by oxygen, and R_{11} is hydrogen or lower alkyl;

by conventional methods.

Preferably the reaction is carried out in a polar organic solvent such as n-butanol.

Preferably R₁₀ is 3-pyridyl and R₁₁ is methyl.

In one embodiment, a compound of formula I wherein R₆ is NHC(NH)NH₂, R₇ is methyl and R₈ is hydrogen may e.g. be treated with 3-dimethylamino-1-(3-pyridyl)-2-propen-1-one to a compound of formula IV wherein R₆' is 4-(3-pyridyl)-2-pyrimidinamino, R₇' is methyl and R₈' is hydrogen, corresponding to the compound of formula IV as described in example 21 of EP 564 409. A compound of formula I wherein R₆ is Br, R₇ is methyl and R₈ is hydrogen may e.g. be treated with 4-(3-pyridyl)-2-pyrimidine-amine, e.g. as available from Chempacific, in the presence of Pd(0) or Pd(II) in the presence of a phosphine ligand to give compound of formula IV wherein R₆' is 4-(3-pyridyl)-2-pyrimidinamino, R₇' is methyl and R₈' is hydrogen.

In another embodiment, compounds of formula I wherein R₆ is NO₂, R₇ is methyl and R₈ is hydrogen may e.g. be transformed to a compound of formula I wherein R₆ is NH₂, R₇ is methyl and R₈ is hydrogen using standard methods known to the skilled person. Compounds of formula I wherein R₆ is halogen, NHC(O)CF₃ or NHC(O)CH₃, preferably Br, R₇ is methyl and R₈ is hydrogen may e.g. be transformed to a compound wherein R₆ is NH₂, R₇ is methyl and R₈ is hydrogen using standard methods known to the skilled person. Compounds of formula I wherein R₆ is NH₂, R₇ is methyl and R₈ is hydrogen may e.g. be transformed to a compound of formula I wherein R₆ is NHC(NH)NH₂, R₇ is methyl and R₈ is hydrogen.

Accordingly, the present invention provides a process for the preparation of compounds of formula IV wherein in a first step a compound of formula I is prepared from compounds of formula II and III as hereinabove described, preferably in the presence of AlCl₃, Al(lower alkyl)₃ e.g. AlMe₃, AlEt₃, Al(iBu)₃ or SOCl₂, and in a second step the compound of formula I is reacted to a compound of formula IV by conventional methods. Preferably, said process is provided for preparation of a compound of formula IV wherein R₁, R₂, R₄, R₅ and R₈' are hydrogen, R₃ is (4-methyl-piperazinyl)-methyl, R₆' is 4-(3-pyridyl)-2-pyrimidinamino, and R₇' is methyl.

- 12 -

The processes of the present invention allow the synthesis of compounds of formula IV, preferably a compound of formula IV wherein R₁, R₂, R₄, R₅ and R₈' are hydrogen, R₃ is (4-methyl-piperazinyl)-methyl, R₆' is 4-(3-pyridyl)-2-pyrimidinamino, and R₇' is methyl, in a more efficient and higher yielding manner than previously described in the literature e.g. in EP 564409. No expensive coupling reagents have to be used. The higher throughput combined with less steps as in the prior art will result in significantly lower production costs. In the previously described syntheses, mutagenic intermediates may be formed. In the processes of the present invention all intermediates show a negative AMES Test (a specific test for mutagenicity; performed according to the OECD Guideline for Testing of Chemicals, 471: Bacterial Reverse Mutation Test, Adopted July 21, 1997) which is a strong indication that no mutagenic intermediates are formed which would be a significant improvement of occupational health. Furthermore, these processes allow the synthesis of e.g. radiolabeled compounds.

Following is a description by way of example only of the process of the present invention.

AlMe ₃	trimethylaluminium	from FLUKA
Al(<i>i</i> Bu) ₃	triisobutylaluminium	from FLUKA
AlCl ₃	aluminium trichloride	from Merck
platinum on sulfide carbon		from Acros
thionyl chloride		from FLUKA
Celite Filter Cel		from FLUKA
Rochelle Salt	potassium-sodium tartrate	from FLUKA
platinum on carbon		from Engelhardt
cyanamide		from FLUKA
3-dimethylamino-1-pyridin-3-yl-propenone		from FLUKA
sodium- <i>tert.</i> -butylate		from FLUKA
<i>rac</i> -BINAP	2,2'-bis-(diphenylphosphino)-1,1'-binaphthalin	
	synthesized according to literature procedure	
Pd ₂ (dba) ₃ *CHCl ₃	tris(dibenzylideneacetone)-dipalladium chloroform complex	from FLUKA

- 13 -

Preference is given above all especially to the compound of formula IV which is N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine. N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine (also known as "Imatinib" [International Non-proprietary Name]) and the use thereof, especially as an anti-tumour agent, are described in Example 21 of European patent application EP-A-0 564 409, which was published on 6 October 1993, and in equivalent applications and patents in numerous other countries, e.g. in US patent 5,521,184 and in Japanese patent 2706682. Another preference is given to the β -crystal form of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide methanesulfonate as described in the European patent application No. 998 473 published on May 10, 2000.

The term "4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide" includes the β -crystal form as described in the European patent application No. 998 473.

Very preferably a compound of formula IV is in the form of a pharmaceutically acceptable salt, especially in the form of its monomesylate salt.

The compounds of formula IV are generically and specifically disclosed in the patent applications EP 0 564 409 A1 and WO 99/03854, in particular in the compound claims and the final products of the working examples, the subject-matter of the final products, the pharmaceutical preparations and the claims are hereby incorporated into the present application by reference to these publications. Comprised are likewise the corresponding stereoisomers as well as the corresponding polymorphs, e.g. crystal modifications, which are disclosed therein.

Thus in a further aspect this invention relates to the use of compounds of formula I for the synthesis of compounds of formula IV, especially 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof or crystal form thereof.

Furthermore, this invention also relates to a pharmaceutical composition comprising,
a) one or more pharmaceutically acceptable excipients,

- 14 -

- b) at least one pharmaceutically active compound of formula IV, and
 c) between 0.00001% and 5% by weight of at least one compound of formula I, preferably between 0.00001% and 0.1%, most preferably between 0.0001% and 0.1% .

The present invention particularly relates to pharmaceutical compositions especially tablets comprising 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or a pharmaceutically acceptable salt or crystal form thereof.

Preferably c) is a compound of formula I wherein, R₃ is (4-methyl-piperazinyl)-methyl, R₁, R₂, R₄, R₅ and R₈ are hydrogen, R₆ is Br, Cl, NH₂, NO₂, NHC(O)CF₃, NHC(O)CH₃ or NHC(NH)NH₂, and R₇ is methyl, or a salt thereof.

One or more pharmaceutically acceptable excipients may be present in the composition, e.g. those conventionally used, e.g. (1.1) at least one binder, e.g. microcrystalline cellulose, hydroxypropylmethyl cellulose, (1.2) at least one disintegrant, e.g. cross-linked polyvinylpyrrolidinone, e.g. Crospovidone®, (1.3) at least one glidant, e.g. colloidal silicon dioxide, (1.4) at least one lubricant, e.g. magnesium stearate and/or (1.5) basic coating. In the tablet according to the present invention, microcrystalline cellulose is used as a binder.

Example A: Capsules with Imatinib (4-[(4-methyl-1-piperazin-1-ylmethyl)-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide) methanesulfonate of formula IV, β-crystal form.

Capsules containing 119.5 mg of the compound named in the title (= SALT I) corresponding to 100 mg of Imatinib (free base) as active substance are prepared in the following composition. The composition containing also compounds of formula I wherein, R₃ is (4-methyl-piperazinyl)-methyl, R₁, R₂, R₄, R₅ and R₈ are hydrogen, R₆ is Br, Cl, NH₂, NO₂, NHC(O)CF₃, NHC(O)CH₃, NHC(NH)NH₂, and R₇ is methyl.

Composition

SALT I	119.5 mg
Compounds of formula I	0.0005mg
Cellulose MK GR	92 mg
Crospovidone XL	15 mg
Aerosil 200	2 mg

- 15 -

Magnesium stearate	1.5 mg

	230.0005 mg

The capsules are prepared by mixing the components and filling the mixture into hard gelatin capsules, size 1.

Example 1

Preparation of *N*-(4-Methyl-3-bromo-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

A solution of trimethylaluminium (2M in toluene, 15.0 ml) is added over a period of 30 min to a solution of 3-bromo-4-methyl-aniline (2.15 g, 11.5 mmol) and 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester (2.87 g, 11.5 mmol) in toluene (20 ml) at 40°C under an atmosphere of argon. After gas evolution ceases, the reaction mixture is stirred 30 min before being cooled to 0°C and partitioned between cold aqueous 1N NaOH (100 ml) and toluene (100 ml). The organic layer is extracted with aqueous saturated NH₄Cl (100 ml) and aqueous saturated NaCl (100 ml). The organic layer is concentrated *in vacuo* to give 4.69 g (97 area% by HPLC) of the title compound as pale yellow crystals.

4-(4-Methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester is obtained as follows:

A solution of 4-formyl-benzoic acid methyl ester (10.0 g, 61 mmol) in methanol (100 ml) is treated sequentially with 1-methylpiperazine (6.7 g, 67 mmol) and platinum (5%) on sulfided carbon (0.5 g). The resulting solution is then heated at 90°C and is subjected to a pressure of 5 bar of hydrogen for a period of 4 hrs until the hydrogen uptake is complete. The reaction mixture is cooled to room temperature and filtrated over a pad of Celite. The methanol is removed under reduced pressure and replaced with toluene (100 ml). The resulting organic solution is extracted with aqueous HCl (2N, 2 x 50 ml). The aqueous layer is treated with concentrated aqueous NaOH (30%) to set the pH to 12 and is back-extracted with toluene (2 x 50 ml). The combined organic layers are concentrated *in vacuo* to give 12.9 g (85%) of 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester as a pale yellow oil which may be further purified by distillation under reduced pressure.

Example 2A

Preparation of *N*-(4-Methyl-3-nitro-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

A solution of trimethylaluminium (2M in toluene, 1.3 ml, 2.6 mmol) is added over a period of 5 min to a solution of 3-nitro-4-methyl-aniline (152 mg, 1.00 mmol) and 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester (248 mg, 1.00 mmol) in toluene (3.0 ml) at 45°C under

- 16 -

an atmosphere of argon. After gas evolution ceases, the dark brown reaction mixture is stirred 30 min before being cooled to 0°C. An aqueous saturated solution of potassium-sodium tartrate (20 ml), *t*-butyl methyl ether (15 ml) and methylene chloride (10 ml) are added sequentially. The organic phase is separated and washed with aqueous saturated NaHCO₃ (10 ml) and aqueous saturated NaCl (10 ml). The aqueous phases are back-extracted with *t*-butyl methyl ether (2 x 15 ml). The organic phases are combined, dried over MgSO₄ and concentrated *in vacuo* to give 383 mg (96 area% by HPLC) of the title compound as pale yellow crystals.

Example 2B:

Preparation of N-(4-Methyl-3-nitro-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

To a solution of 10.95 g (72 mmol) of 3-nitro-4-methyl-aniline in 80 ml of toluene is added a solution of triisobutylaluminium (28 % in hexane), 66.5 ml (61 mmol) over a period of 30 min at 0°C followed by the addition of a solution of 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester (14.9 g, 60 mmol) in toluene (30 ml) during 1 hour at 0 °C under an atmosphere of argon. After stirring for 12 h at room temperature an other portion of triisobutylaluminium (66.5 ml (61 mmol) is added to the dark brown reaction mixture. The mixture is stirred for additional 6 h, then 2 additional small portions of triisobutylaluminium (each 18 ml , 18 mmol) are added and stirring is continued for several hours at room temperature. After acidic and basic workup with sulfuric acid and NaOH the combined organic toluene phases are evaporated *in vacuo* to give a brown crude product which was crystallized from *t*-butyl methyl ether to give the title compound as brownish yellow crystals: first crop (11.65 g), sec. crop (3.8 g) and a third crop (1.2 g). in summary 16.65 g (75.3 %).

Example 2C:

Preparation of N-(4-methyl-3-nitro-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

4-methyl-3-nitroaniline (30.0 g, 0.197 mol) is added to a mixture of tetrahydrofuran (120 ml) and *N*-ethyl-*N,N*-diisopropyl-amine at 23-25 °C over a period of 5 to 10 min. To this solution chloromethyl-benzoylchloride (38.4 g, 0.20 mol) dissolved in tetrahydrofuran (35 ml) is added over a period of 60-65 min maintaining a temperature of 25-30 °C. The reaction mixture is

- 17 -

stirred at this temperature for 30 min and then added to *N*-methylpiperazine (138.2g, 1.38 mol) over a period of 60 to 90 °C maintaining a temperature of 25-30 °C. The resulting suspension is stirred at this temperature for 60 min. Tetrahydrofuran is distilled off at 50 °C under reduced pressure. At the end of the distillation the temperature is adjusted to 45-48 °C and water (300 ml) is added over a period of 45-60 min at this temperature. The resulting suspension is cooled to 23 °C and stirred for 60 min. The suspension is filtered, the filtercake washed with water (225 ml) and dried *in vacuo* to give 69.2 g of the title compound (95 % of theory) as an off-white powder (99.5 % area by HPLC).

Alternatively the intermediate *N*-(4-methyl-3-nitro-phenyl)-4-chloromethyl-benzamide can be isolated by distilling off half of the tetrahydrofuran under reduced pressure and adding the residue to water (300 ml) at a temperature of 20-25 °C over a period of 30 min. After stirring for another 30 min at 0-5 °C, the suspension is filtered, washed with water (200 ml) and dried *in vacuo*. The intermediate is dissolved in tetrahydrofuran (150 ml) and added to *N*-methylpiperazine (138.2g, 1.38 mol) over a period of 60 to 90 min maintaining a temperature of 25-30 °C. The title compound can be isolated following the above described procedure.

Example 3

Preparation of *N*-(4-Methyl-3-trifluoroacetimidate-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

A solution of trimethylaluminum (2M in toluene, 1.25 ml, 2.5 mmol) is added over a period of 5 min to a solution of 3-trifluoroacetimidate-4-methyl-aniline (218 mg, 1.00 mmol) and 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester (248 mg, 1.00 mmol) in toluene (3.0 ml) at 0°C under an atmosphere of argon. After gas evolution ceases, the dark brown reaction mixture is stirred 3 hrs at 23°C before being cooled to 0°C. An aqueous saturated solution of potassium-sodium tartrate (20 ml) and *t*-butyl methyl ether (40 ml) are added sequentially. The organic phase is separated and washed with aqueous saturated NaHCO₃ (20 ml) and aqueous saturated NaCl (20 ml). The aqueous phases are back-extracted with *t*-butyl methyl ether (2 x 20 ml). The organic phases are combined, dried over MgSO₄ and concentrated *in vacuo* to give 458 mg (94 area% by HPLC) of the title compound as white crystals.

Example 4

Preparation of *N*-(3-amino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

- 18 -

A solution of AlCl_3 (1000 mg, 7.5 mmol) in toluene (3 ml) and acetonitrile (3.0 ml) at 0°C under an atmosphere of argon is treated dropwise with a solution of 3-amino-4-methylaniline (470 mg, 6.0 mmol) in toluene (6 ml). The resulting brown solution is heated at 40°C . A solution of 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester (745 mg, 3.0 mmol) in toluene (2 ml) is then added dropwise over a period of 30 min. The resulting mixture is stirred at 40°C for 8 hrs and then cooled at 0°C . An aqueous saturated potassium-sodium tartrate (30 ml) and aqueous saturated NaHCO_3 (40 ml) and *t*-butyl methyl ether (60 ml) are added sequentially. The organic phase is separated and washed with aqueous saturated NaCl. The aqueous phases are back-extracted with *t*-butyl methyl ether. The organic phases are combined, dried over MgSO_4 and concentrated *in vacuo*. Purification by flash-chromatography (SiO_2 , $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 90:10 + 1% aq. NH_3) gives 825 mg of the title compound (75%) as yellowish crystals.

Example 5

Preparation of N-(4-methyl-3-nitro-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

Thionyl chloride (53.3 g, 448 mmol) is added over a period of 15 min to a suspension of 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid (70.0 g, 299 mmol) in toluene (300 ml) at 0°C . At the end of the addition, the reaction mixture is heated at 23°C over a period of 45 min. The excess of SOCl_2 is removed by co-distillation with toluene under reduced pressure at 40°C . At the end of the distillation, the resulting suspension is cooled down to 0°C and the benzoyl chloride is filtered off, washed with toluene (2 x 50 ml) and dried *in vacuo* at 45°C overnight. Yield: 55.0 g, 79% of theory based on the di-hydrochloride salt of the benzoyl chloride, white solid. The dried benzoyl chloride (55g) is then resuspended in toluene (100 ml). A solution of 4-methyl-3-nitroaniline (22.75 g, 145 mmol) and pyridine (34.4 g, 435 mmol) in toluene (60 ml) is added dropwise at 23°C over a period of 15 min. The resulting orange-brown reaction mixture is heated at 45°C and is stirred for 6 hrs. The suspension is filtrated and the filtercake is washed successively with toluene (300 ml) and acetone (350 ml), and is then suspended in water (350 ml). Aqueous NaOH (30%) is added until the pH of the suspension reaches 11 and remains stable. The suspension is further stirred for 1h at 40°C before being filtrated. The filtercake is washed with water (5 x 50 ml) and dried *in vacuo* to give 51.3 g of the title compound (96%) as beige crystals, (98.7% area by HPLC).

Preparation of 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid:

A suspension of 4-formyl-benzoic acid (10.0 g, 67 mmol) in methanol (100 ml) is treated sequentially with 1-methylpiperazine (7.3 g, 73 mmol) and platinum (5%) on sulfided carbon

(1 g). The resulting suspension is then heated at 80°C and is subjected to a pressure of 5 bar of hydrogen for a period of 20 hrs until the hydrogen uptake is complete. The reaction mixture is cooled to room temperature and filtrated over a pad of Celite. Water (20 ml) is used to rinse the reactor and dissolve the fraction of 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid that crystallizes on the walls during the cooling of the reaction mixture. The resulting aqueous solution is filtrated over the pad of Celite employed previously. The combined filtrates are concentrated *in vacuo* and crystallized in EtOH/H₂O 9:1 v/v to give 10.9 g (70%) of 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid as colorless crystals.

Example 6

Preparation of *N*-(3-guanidino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

In analogous manner to Example 4, 3-guanidino-4-methyl-aniline (2.51 g, 11.5 mmol) and 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid (70.0 g, 299 mmol) in toluene (300 ml) in the presence of thionyl chloride (53.3 g, 448 mmol) give 12.1 g (89%) of the title compound as pale colorless crystals.

Example 7

Preparation of 4-dichloromethyl-*N*-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide:

To a suspension of 4-methyl-*N**(3)-(4-pyridin-3-yl-pyrimidin-2-yl)-benzene-1,3-diamine (2.00g mg, 7.21 mmol) in toluene (22 ml) at 45°C under an atmosphere of argon is added sequentially 4-dichloromethyl-benzoic acid methyl ester (1.90 g, 8.67 mmol) and AlMe₃ (2 M in toluene, 12.6 ml, 25.2 mmol). The resulting brown solution is stirred at 45°C for a period of 3.5 hrs. The reaction mixture is then cooled to 0°C and quenched by slow addition of a saturated aqueous solution of Rochelle salt (70 ml) which causes the precipitation of the crude product. *t*-Butyl methyl ether (150 ml) and methylene chloride (100 ml) are added sequentially to the suspension which are then washed with aqueous saturated NaHCO₃ (100 ml) and aqueous saturated NaCl (100 ml). The aqueous phases are back-extracted with *t*-butyl methyl ether (100 ml). The crude product, which is contained in the combined organic phases, is filtered off with suction, washed with *t*-butyl methyl ether and dried *in vacuo*. Yield: 3.35 g of the title compound, 84% of theory, as beige crystals, (HPLC: 91% area).

Example 8

Preparation of *N*-(3-guanidino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

In analogous manner to Example 4, 3-guanidino-4-methyl-aniline (1.00 g, 6.09 mmol) and 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester (1.50 g, 6.04 mmol) in toluene (22 ml) and acetonitrile (6 ml) in the presence of AlCl_3 (2.0 g, 15.0 mmol) at 40°C give 1.26 g (55%) of the title compound as pale colorless crystals.

Example 9

Preparation of 4-(4-methyl-piperazin-1-ylmethyl)-*N*-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide:

A suspension of *N*-(3-guanidino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (30 g, 79 mmol) in *n*-butanol (150 ml) at 120°C under an atmosphere of nitrogen is treated with 3-dimethylamino-1-pyridin-3-yl-propenone (15.3 g, 87 mmol). The resulting suspension is heated at 150°C for 5 hrs. The reaction mixture becomes a homogeneous deep orange solution and dimethylamine is removed by the distillation of *n*-butanol (130 ml). *n*-Butanol (20 ml) is added during the distillation. Butyl acetate (60 ml) is added dropwise at 100°C and the solution is cooled to 0°C within 1 hr and stirred at 0°C for 16 hrs. The resulting deep orange suspension is filtered off with suction, the isolated solid is washed with *n*-butanol (2 x 50 ml) and water (2 x 50 ml) and dried *in vacuo* at 60°C. Yield: 36.4 g of the title compound, 93% based on theory, as off-white crystals. (99.6% area by HPLC).

Example 10

Preparation of 4-(4-methyl-piperazin-1-ylmethyl)-*N*-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide:

To a mixture of 4-(3-pyridyl)-2-pyrimidine-amine (172.2 mg, 1.0 mmol), *N*-(3-bromo-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (402.4 mg, 1.0 mmol) and sodium *tert*-butylate (144.2 mg, 1.5 mmol) is added a mixture of *rac*-BINAP (31.2 mg, 0.050 mmol) and $\text{Pd}_2(\text{dba})_3 \cdot \text{CHCl}_3$ (13 mg, 0.013 mmol) under argon. After addition of 3 ml of xylene the suspension is sonicated for 10 minutes then stirred for 5 hours under reflux. After cooling to room temperature, water (10 ml) is added to the dark brown oil and the product extracted 4 times with methylene chloride (10 ml each). The combined organic extracts are dried over MgSO_4 and concentrated *in vacuo*. The brown oil is purified by flash-chromatography (SiO_2 , methanol). The product, a pale yellow solid is dissolved in methylene chloride, filtered and concentrated *in vacuo*. Yield: 484.3 mg of the title compound, 72% of

theory, (99.9% area by HPLC). The product contains typically roughly 10% of isomers which can be eliminated by preparative reversed phase chromatography.

Example 11

Preparation of *N*-(3-amino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

A solution of *N*-(4-methyl-3-nitro-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (100 g, 260 mmol) in *n*-butanol (1 l) is treated with platinum (5%) on carbon (1.0 g). The resulting suspension is then heated to 70°C and hydrogen is applied with a pressure of 0.2 bar for a period of 6 h until the hydrogen uptake is complete. The reaction mixture is cooled to room temperature and filtrated. *n*-Butanol is used to wash the catalyst. This solution is suitable for example 12. For isolation of the product is reduced to a third and crystallized by cooling down to 0 °C (HPLC: 98.0% area).

Alternatively a solution of *N*-(4-methyl-3-nitro-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (60 g, 163 mmol) in ethanol 90% (300 ml) at room temperature under an atmosphere of nitrogen is treated sequentially with platinum (5%) on carbon (6.0 g) and potassium formate (68.5 g, 814 mmol). The resulting suspension is then heated at 80°C for a period of 16 hrs. The reaction mixture is filtrated at 70°C over a pad of Celite. Ethanol 90% (150 ml) and water (150 ml) are used to rinse the reactor. Ethanol is removed from the combined filtrates by distillation *in vacuo* at an external temperature 60°C. The crude product separates from the aqueous concentrate as an oil during the distillation, crystallizes upon subsequent cooling to 23°C within 2 hrs and is filtered off with suction, washed with ethanol (200 ml) and dried *in vacuo*. Yield: 55 g of the title compound, 99% of theory, as yellowish crystals. (HPLC: 98.0% area).

Example 12

Preparation of *N*-(3-guanidino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide:

A suspension of *N*-(3-amino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-ylmethyl)-benzamide (50 g, 144 mmol) in *n*-butanol (300 ml) at 85°C is treated sequentially with concentrated aqueous HCl until the pH reaches 2.5 (HCl 37%, 35 g) and with a solution of cyanamide (12.1 g, 288 mmol) in water (12 ml) over a period of 30 min. The resulting reaction mixture is stirred at 85°C for 20 hrs during which time the starting material dissolves and the desired product crystallizes out of solution as the di-hydrochloride salt. Concentrated HCl (37%, 6.3 g) is added during the reaction to maintain the pH at 2.5. The reaction mixture is then


- 22 -

allowed to cool down to room temperature within 1.5 hrs. The product is filtered off with suction, washed with n-butanol (3 x 50 ml) and dried *in vacuo* at 60°C. Yield 60.7 g of the di-hydrochloride salt, 93% of theory (99% area by HPLC).

The di-hydrochloride salt is dissolved in water (250 ml) at 35°C. An aqueous solution of NaOH (2N, 150 ml) is added and the pH of the solution increases to 13.2. The desired product separates from the aqueous solution as an oil which crystallizes upon cooling to 0°C. After 1 hr stirring at 0°C, the product is filtered off, washed with an aqueous solution of K₂CO₃ (5.5 g/L, 2 x 50 ml) and dried *in vacuo* at 50°C. Yield: 41.2 g of the title compound, 89% of theory based on the intermediate di-hydrochloride salt, as beige crystals, (98.7% area by HPLC).

Claims

1. A compound of formula I



wherein

one of the radicals R_1 , R_2 , R_3 , R_4 and R_5 is

- a) a radical selected from the group consisting of lower alkyl, amino; mono- or di-lower alkylamino; lower alkanoylamino; lower alkoxy-carbonyl; and lower alkyl which is substituted by amino, mono- or di-lower alkylamino or lower alkanoylamino, or
- b) an unsubstituted or substituted radical selected from the group consisting of benzylamino; benzoylamino; pyrrolidinyl; piperidyl; piperazinyl; piperazinyl-carbonyl; morpholinyl; thiomorpholinyl; and lower alkyl substituted by benzylamino, benzoylamino, halogene, pyrrolidinyl, piperidyl, piperazinyl, e.g. 4-methyl-piperazinyl-, thiomorpholinyl, or morpholinyl, the substituents of said substituted radical being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen, and

and the other four radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

or

R_1 and R_2 , R_2 and R_3 , R_3 and R_4 , or R_4 and R_5 together are a substituted or unsubstituted alkylene radical having 4 carbon atoms, the substituents preferably being selected from cyano, unsubstituted or hydroxy-, amino- or 4-methyl-piperazinyl-substituted lower alkyl, such as especially methyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino and free or esterified carboxy;

and the other three radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower

- 24 -

alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxycarbonyl and halogen;

and one of the radicals R_6 , R_7 and R_8 is halogen NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, or $NHC(NH)NH_2$, and the other two radicals are hydrogen, lower alkyl, lower fluorinated alkyl, benzyl or phenyl;

or a salt or crystal form thereof.

2. A compound according to claim 1 wherein R_6 is halogen, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, or $NHC(NH)NH_2$, R_7 is methyl and R_8 is hydrogen.

3. A compound according to claim 2 wherein R_6 is Br or $NHC(NH)NH_2$.


4. A compound according to any preceding claim wherein R_3 is lower alkyl substituted by benzylamino, benzoylamino, halogene, pyrrolidinyl, piperidyl, piperazinyl, e.g. 4-methyl-piperazinyl-, thiomorpholinyl, or morpholinyl, the substituents of said substituted radical being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxycarbonyl and halogen.

5. A compound according to any preceding claim wherein R_3 is (4-methyl-piperazinyl)-methyl.

6. A compound according to any preceding claim wherein R_3 is (4-methyl-piperazinyl)-methyl, and R_1 , R_2 , R_4 , and R_5 are hydrogen.

7. A compound according to any preceding claim wherein the salt is selected from chloride, bromide, mesylate, acetate or trifluoroacetate.

8. Process for the preparation of a compound of formula I



wherein

one of the radicals R_1 , R_2 , R_3 , R_4 and R_5 is

- a) a radical selected from the group consisting of lower alkyl, amino; mono- or di-lower alkylamino; lower alkanoylamino; lower alkoxy-carbonyl; and lower alkyl which is substituted by amino, mono- or di-lower alkylamino or lower alkanoylamino, or
- b) an unsubstituted or substituted radical selected from the group consisting of benzylamino; benzoylamino; pyrrolidinyl; piperidyl; piperazinyl; piperazinyl-carbonyl; morpholinyl; thiomorpholinyl; and lower alkyl substituted by benzylamino, benzoylamino, halogen, pyrrolidinyl, piperidyl, piperazinyl, e.g. 4-methyl-piperazinyl-, thiomorpholinyl, or morpholinyl, the substituents of said substituted radical being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen, and

and the other four radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

or

R_1 and R_2 , R_2 and R_3 , R_3 and R_4 , or R_4 and R_5 together are a substituted or unsubstituted alkylene radical having 4 carbon atoms, the substituents preferably being selected from cyano, unsubstituted or hydroxy-, amino- or 4-methyl-piperazinyl-substituted lower alkyl, such as especially methyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino and free or esterified carboxy;


- 26 -

and the other three radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxycarbonyl and halogen;


and one of the radicals R_6 , R_7 and R_8 is halogen, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, $NHC(NH)NH_2$, and the other two radicals are hydrogen, lower alkyl, fluorinated lower alkyl benzyl or phenyl;

or a salt or crystal form thereof,

wherein a compound of formula II



is reacted with an amine of formula III



A) wherein R_9 = methyl, ethyl or aryl: in the presence of


- 1) a Lewis acid selected from $Al(\text{lower alkyl})_3$, $AlCl_3$, $EtAlCl_2$, $MeAlCl_2$, Me_2AlCl , Et_2AlCl or the corresponding sesquichlorides,
 - 2) an organic solvent, and optionally
 - 3) a base,
- and the resulting product is hydrolyzed;

or

B) wherein R_9 = hydrogen: in the presence of

- 27 -

- 1) thionylchloride,
 - 2) an organic solvent, and optionally
 - 3) a base.
9. A process according to claim 8 wherein the Lewis acid in A) is selected from AlMe_3 , AlEt_3 , $\text{Al}i\text{Bu}_3$, AlCl_3 , EtAlCl_2 and Et_2AlCl .
 10. A process according to claim 8 or 9 wherein the process is carried out at a temperature of 20°C to 80°C .
 11. A process according to any one of claims 8 to 10 wherein R_1 , R_2 , R_4 , R_5 , and R_8 are hydrogen, R_3 is (4-methyl-piperazinyl)-methyl, R_6 is halogen, NH_2 , NO_2 , NHC(O)CF_3 , NHC(O)CH_3 , or NHC(NH)NH_2 , and R_7 is methyl.
 12. A process for the preparation of compounds of formula I



wherein

the radicals R_1 , R_2 , R_4 and R_5 are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

or

R_1 and R_2 or R_4 and R_5 together are a substituted or unsubstituted alkylene radical having 4 carbon atoms, the substituents preferably being selected from cyano, unsubstituted or hydroxy-, amino- or 4-methyl-piperazinyl-substituted lower alkyl, such as especially methyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino and free or esterified carboxy;

and the other three radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower

- 28 -


alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

and R_3 is a lower alkyl substituted by benzylamino, benzoylamino, pyrrolidinyl, piperidyl, piperazinyl, optionally substituted by radicals being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl;

and one of the radicals R_6 , R_7 and R_8 is halogen, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, $NHC(NH)NH_2$, and the other two radicals are hydrogen, lower alkyl, fluorinated lower alkyl, benzyl or phenyl,

or a salt or crystal form thereof,

wherein a compound of formula V



is reacted with a compound of formula $R_{14}-H$,

wherein,

R_{13} is a lower alkyl substituted by a halogen, and

R_{14} is benzylamino, benzoylamino, pyrrolidinyl, piperidyl, piperazinyl, optionally substituted by radicals being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl,

or a salt thereof.


13. A process according to claim 12, wherein

$R_{14}-H$ is N-methylpiperazine,

R_{13} is a methyl substituted by a halogen, and

R_1 , R_2 , R_4 , R_5 , and R_8 are hydrogen, R_3 is (4-methyl-piperazinyl)-methyl, R_6 is Br, Cl, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, or $NHC(NH)NH_2$, and R_7 is methyl.

14. The use of compounds of formula I according to any one of claims 1 to 7 for the preparation of compounds of formula IV



wherein

one of the radicals R_1 , R_2 , R_3 , R_4 and R_5 is

- a) a radical selected from the group consisting of lower alkyl, amino; mono- or di-lower alkylamino; lower alkanoylamino; lower alkoxy-carbonyl; and lower alkyl which is substituted by amino, mono- or di-lower alkylamino or lower alkanoylamino, or
- b) an unsubstituted or substituted radical selected from the group consisting of benzylamino; benzoylamino; pyrrolidinyl; piperidyl; piperazinyl; piperazinyl-carbonyl; thiomorpholinyl, morpholinyl; and lower alkyl substituted by benzylamino, benzoylamino, halogene, pyrrolidinyl, piperidyl, piperazinyl, e.g. 4-methyl-piperazinyl-, thiomorpholinyl or morpholinyl, the substituents of said substituted radical being selected from the group consisting of cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen, and

and the other four radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

or


R_1 and R_2 , R_2 and R_3 , R_3 and R_4 , or R_4 and R_5 together are a substituted or unsubstituted alkylene radical having 4 carbon atoms, the substituents preferably being selected from cyano, unsubstituted or hydroxy-, amino- or 4-methyl-piperazinyl-substituted lower alkyl,

- 30 -

such as especially methyl, trifluoromethyl, free, etherified or esterified hydroxy, free, alkylated or acylated amino and free or esterified carboxy;

and the other three radicals are independently hydrogen, cyano; lower alkyl; hydroxy- or amino-substituted lower alkyl; trifluoromethyl; free, etherified or esterified hydroxy; lower alkoxy; lower alkanoyloxy; free, alkylated or acylated amino; mono- or di-lower alkylamino; lower alkanoylamino; benzoylamino; free or esterified carboxy; lower alkoxy-carbonyl and halogen;

and one of the radicals R_6' , R_7' and R_8' is



wherein R_{10} is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen, and R_{11} and R_{12} are each independently of the other hydrogen or lower alkyl

and the other two radicals are hydrogen, lower alkyl, benzyl or phenyl;

or a pharmaceutically acceptable salt or crystal form thereof.

15. The use according to claim 14 of a compound of formula I, wherein R_1 , R_2 , R_4 , R_5 and R_8 are hydrogen, R_3 is (4-methyl-piperazinyl)-methyl, R_6 is Br, Cl, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$, or $NHC(NH)NH_2$, and R_7 is methyl, for the preparation of compound of formula IV, wherein R_1 , R_2 , R_4 , R_5 and R_8' are hydrogen, R_3 is (4-methyl-piperazinyl)-methyl, R_6' is 4-(3-pyridyl)-2-pyrimidinamino, and R_7' is methyl, or a pharmaceutically acceptable salt or crystal form thereof.

16. A process for the preparation of compounds of formula IV or a pharmaceutically acceptable salt or crystal form thereof, from compounds of formula I.

17. A process for the preparation of a compound of formula IV or a pharmaceutically acceptable salt or crystal form thereof, from compounds of formula II and III wherein in a first

step a compound of formula I is prepared according to any one of claims 8 to 13 and in a second step the compound of formula I is reacted to a compound of formula IV by conventional methods.

18. Process according to claim 16 or 17 for the preparation of a compound of formula IV wherein R_1 , R_2 , R_4 , R_5 and R_8 are hydrogen, R_3 is (4-methyl-piperazinyl)-methyl, R_6 is 4-(3-pyridyl)-2-pyrimidinamino, and R_7 is methyl, or a pharmaceutically acceptable salt or crystal form thereof.

19. A pharmaceutical composition comprising,

- a) one or more pharmaceutically acceptable excipients, and
- b) at least one pharmaceutically active compound of formula IV, and
- c) between 0.00001% and 5% by weight of at least one compound of formula I.

20. A pharmaceutical composition according to claim 19, wherein

b) is (4-[(4-methyl-1-piperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide) or a pharmaceutically acceptable salt or crystal form thereof, and

c) is at least one compound of formula I wherein, R_3 is (4-methyl-piperazinyl)-methyl, R_1 , R_2 , R_4 , R_5 and R_8 are hydrogen, R_6 is halogen, NH_2 , NO_2 , $NHC(O)CF_3$, $NHC(O)CH_3$ or $NHC(NH)NH_2$, and R_7 is methyl, or a salt or crystal form thereof.

INTERNATIONAL SEARCH REPORT

Inten Application No
PC1/EP 03/01188

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D295/12 C07C237/40 C07D401/04 C07C233/80

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 564 409 A (CIBA GEIGY AG) 6 October 1993 (1993-10-06) cited in the application page 16; example 21 ---	12-20
X	WO 92 17066 A (BAYER AG) 15 October 1992 (1992-10-15) page 27; example 21 ---	1, 2, 4, 8-11
X	DE 44 28 380 A (BAYER AG) 15 February 1996 (1996-02-15) page 19; example 6 page 12, line 8 - line 31 ---	1-4, 8-11
X	US 3 763 234 A (BRILL W) 2 October 1973 (1973-10-02) the whole document ---	8-11
	-/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

11 April 2003

Date of mailing of the international search report

13/05/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bedel, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/01188

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BASHA A ET AL: "A mild, general method for conversion of esters to amides" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, no. 48, November 1977 (1977-11), pages 4171-4173, XP002197154 ISSN: 0040-4039 the whole document	8-11
X	--- DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 2775102 XP002237975 abstract & GB 862 127 A (IMP.CHEM.IND.) 1 March 1961 (1961-03-01)	1,2
X	--- DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 3005098 XP002237976 abstract & US 3 505 389 A (HOOKER CHEM.) 7 April 1970 (1970-04-07)	1,2
X	--- DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 3401828 XP002237977 abstract & US 2 808 433 A (DUPONT DE NEMOURS) 1 October 1957 (1957-10-01)	1,2
X	--- DATABASE CROSSFIRE BEILSTEIN 'Online! Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; Database accession no. 3411040 XP002237978 abstract page 13, line 5 - line 10 & DE 531 480 C (I.G.FARBENIND.) 10 August 1931 (1931-08-10)	1,2
X	--- WO 99 03854 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); BUEGER HANS MICHA) 28 January 1999 (1999-01-28) cited in the application claims 1,11,12	12-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/01188

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-3, 12 and 4(partially), 14-20 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-3, 12 and 4(partially),14-20 (partially)

The initial phase of the search over the subject-matter of claims 1-3 and 12 revealed a very large number of documents relevant to the issue of novelty. A sample searched of what has been retrieved in Beilstein is presented in the search report as documents D6-D9.

Therefore a search restricted to a combination of claims 2 and 4 had to be done.

A complete search has been done for claims 5-11 and 13.

Claims 14-20 can only be considered as complete insofar as they refer to the domain of formula (I) that has been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Intern I Application No
PCT/EP 03/01188

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0564409	A	06-10-1993	AT 188964 T	15-02-2000
			AU 3569493 A	07-10-1993
			BR 1100739 A3	06-06-2000
			CA 2093203 A1	04-10-1993
			CN 1077713 A ,B	27-10-1993
			CZ 9300560 A3	16-02-1994
			DE 59309931 D1	24-02-2000
			DK 564409 T3	19-06-2000
			EP 0564409 A1	06-10-1993
			ES 2142857 T3	01-05-2000
			FI 931458 A	04-10-1993
			GR 3032927 T3	31-07-2000
			HU 64050 A2	29-11-1993
			IL 105264 A	11-04-1999
			JP 2706682 B2	28-01-1998
			JP 6087834 A	29-03-1994
			KR 261366 B1	01-08-2000
			MX 9301929 A1	29-07-1994
			NO 931283 A	04-10-1993
			NZ 247299 A	26-07-1995
			PT 564409 T	30-06-2000
			RU 2125992 C1	10-02-1999
			SG 43859 A1	14-11-1997
			SK 28093 A3	06-04-1994
			US 5521184 A	28-05-1996
			ZA 9302397 A	04-10-1993
WO 9217066	A	15-10-1992	DE 4110483 A1	01-10-1992
			AU 1562492 A	02-11-1992
			BR 9205820 A	28-06-1994
			WO 9217066 A1	15-10-1992
			EP 0586386 A1	16-03-1994
			HU 65081 A2	28-04-1994
			JP 6509320 T	20-10-1994
			PL 294002 A1	22-03-1993
DE 4428380	A	15-02-1996	DE 4428380 A1	15-02-1996
			AU 3382295 A	07-03-1996
			WO 9605170 A1	22-02-1996
US 3763234	A	02-10-1973	NONE	
GB 862127	A	01-03-1961	NONE	
US 3505389	A	07-04-1970	NONE	
US 2808433	A	01-10-1957	NONE	
DE 531480	C	10-08-1931	NONE	
WO 9903854	A	28-01-1999	AU 740713 B2	15-11-2001
			AU 8975998 A	10-02-1999
			BR 9810920 A	15-08-2000
			CN 1264375 T	23-08-2000
			WO 9903854 A1	28-01-1999
			EP 0998473 A1	10-05-2000
			HU 0003230 A2	28-06-2001
			JP 3276359 B2	22-04-2002

INTERNATIONAL SEARCH REPORT

Intern I Application No

PCT/EP 03/01188

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9903854	A	JP 2001510192 T	31-07-2001
		NO 20000227 A	17-01-2000
		NZ 502295 A	21-12-2001
		PL 338129 A1	25-09-2000
		SK 432000 A3	12-06-2000
		TR 200000060 T2	21-09-2000
		US 2002115858 A1	22-08-2002
		ZA 9806362 A	22-01-1999
